“Long-Term Efficacy of Certolizumab Pegol Dosed at 400 mg Every Two Weeks in Patients with Plaque Psoriasis: Pooled 128-Week Data from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2)”, J of Skin, vol. 3, p. S36, Nov. 2019, doi: 10.25251/skin.3.supp.36.